Integer Holdings Corporation Common Stock (ITGR)
117.44
-3.64 (-3.01%)
NYSE · Last Trade: Apr 3rd, 11:14 AM EDT
Via Benzinga · March 28, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Via StockStory · February 28, 2025

Via Benzinga · February 21, 2025

Medical technology company Integer Holdings (NYSE:ITGR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 11.1% year on year to $449.5 million. The company’s full-year revenue guidance of $1.86 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.43 per share was 2% below analysts’ consensus estimates.
Via StockStory · February 20, 2025

Via Benzinga · January 24, 2025

Medical technology company Integer Holdings (NYSE:ITGR)
will be announcing earnings results tomorrow before market hours. Here’s what you need to know.
Via StockStory · February 19, 2025

Via Benzinga · October 21, 2024

ITGR stock results show that Integer Holdings beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · July 25, 2024

Esther Takeuchi tackled a tough first project after joining private company Greatbatch.
Via Investor's Business Daily · July 25, 2024

Via Benzinga · July 16, 2024

Via Benzinga · May 15, 2024

Via Benzinga · April 26, 2024

Truist Securities initiates coverage on Integer. With a Buy rating and a $137 target, Integer is poised for significant gains driven by organic growth and strategic acquisitions.
Via Benzinga · May 15, 2024

ITGR stock results show that Integer Holdings beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · April 25, 2024

BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in 2023 to over $2 billion in 2025, Integer emerges as a key supplier for major PFA device manufacturers
Via Benzinga · April 15, 2024

Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year.
Via Investor's Business Daily · March 26, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via Benzinga · February 15, 2024

The Relative Strength (RS) Rating for Edwards Lifesciences stock jumped into a new percentile Tuesday, with a rise from 78 to 81.
Via Investor's Business Daily · March 19, 2024

On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78.
Via Investor's Business Daily · March 11, 2024